https://www.cnbc.com/2018/05/30/after-hours-buzz-crsp-box-more.html

Check out the companies making headlines after the bell on Wednesday:

Shares of CRISPR Therapeutics plunged 18.5 percent in extended trading. The biotechnology company disclosed that the FDA has placed a clinical hold on its drug application for a sickle cell disease stem cell therapy. The suspension will be in effect until CRISPR and Vertex Pharmaceuticals answer FDA questions about the drug application.